Epic Sciences

In the News


Epic's San Diego lab gains CLIA certification.

San Diego, Epic Sciences — Epic Sciences has received its Clinical Laboratory Improvement Amendments (CLIA) license from the Centers for Medicare and Medicaid Services and the State of California for its circulating tumor cell lab in San Diego to advance new cancer diagnostics.


Epic's CSO, Dena Marinucci, named to PharmaVOICE 100.

PharmaVOICE — PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine's 2015 list of 100 outstanding professionals in the life-sciences industry. Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.


GenomeWeb: Epic Sciences collaborators share data at AACR on single cancer cell analysis, CTC biomarker detection.

New York, GenomeWeb — GenomeWeb reported from the annual meeting of the American Association for Cancer Research (AACR), where several research groups presented studies using Epic Science's no cell left behind™ platform for detecting and analyzing circulating tumor cells (CTCs).


Epic Sciences to present at the Piper Jaffray Healthcare Conference.

Epic Sciences today announced that Murali Prahalad, Ph.D., president and CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 9:30 a.m. ET at The New York Palace in New York City.


Lung Cancer News Today — Epic Sciences to present CTC-CFDNA method for lung cancer analysis.

Innovative cancer diagnostics and treatment development company, Epic Sciences, Inc., will be attending the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona to present a poster on a method to comprehensively detect clinically actionable non-small cell lung cancer (NSCLC) biomarkers using circulating tumor cells (CTCs) and circulating free DNA (cfDNA).


Cancer Discovery: Tracking CTCs may improve cancer treatment.

Cancer Discovery — Epic Sciences' circulating tumor cell (CTC) no cell left behind™ technology was featured in Cancer Discovery's May 2014 issue. The article discusses how quantifying and characterizing circulating tumor cells (CTC), as a liquid biopsy, is helping doctors to determine the course of therapy and to watch how a patient’s cancer evolves — all with a blood draw.


The Scientist: Capturing cancer cells on the move.

The Scientist — Epic's circulating tumor cell (CTC) technology was featured in the April 2014 issue of The Scientist. The article discusses how our no cell left behind™ technology can capture all of the CTCs in a blood sample, because Epic's approach does not rely on cell-enrichment strategies.